desmopressin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| vasoconstrictors, vasopressin derivatives | 817 | 16679-58-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 25 | mcg | N |
| 0.40 | mg | O |
| 4 | mcg | P |
| 0.24 | mg | SL |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 47 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.00 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 15 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.30 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 21, 1978 | FDA | FERRING PHARMS INC | |
| June 18, 2019 | PMDA | FERRING PHARMACEUTICALS CO., LTD. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyponatraemia | 553.34 | 18.77 | 244 | 5203 | 101895 | 56184725 |
| Hyponatraemic encephalopathy | 177.87 | 18.77 | 29 | 5418 | 211 | 56286409 |
| Craniopharyngioma | 109.32 | 18.77 | 18 | 5429 | 140 | 56286480 |
| Recalled product administered | 107.31 | 18.77 | 21 | 5426 | 463 | 56286157 |
| Hyponatraemic seizure | 103.35 | 18.77 | 20 | 5427 | 415 | 56286205 |
| Diabetes insipidus | 96.57 | 18.77 | 26 | 5421 | 2411 | 56284209 |
| Water intoxication | 79.41 | 18.77 | 16 | 5431 | 411 | 56286209 |
| Hypernatraemia | 78.48 | 18.77 | 28 | 5419 | 6592 | 56280028 |
| Seizure | 74.25 | 18.77 | 75 | 5372 | 125044 | 56161576 |
| Poor quality product administered | 69.95 | 18.77 | 21 | 5426 | 2878 | 56283742 |
| Blood sodium decreased | 59.20 | 18.77 | 33 | 5414 | 22301 | 56264319 |
| Renal salt-wasting syndrome | 59.09 | 18.77 | 12 | 5435 | 321 | 56286299 |
| Pharyngeal haemorrhage | 58.59 | 18.77 | 13 | 5434 | 535 | 56286085 |
| Adrenocortical insufficiency acute | 54.58 | 18.77 | 15 | 5432 | 1501 | 56285119 |
| Brain injury | 50.29 | 18.77 | 20 | 5427 | 6335 | 56280285 |
| Patent ductus arteriosus | 47.92 | 18.77 | 17 | 5430 | 3934 | 56282686 |
| Tonsillar disorder | 44.93 | 18.77 | 12 | 5435 | 1078 | 56285542 |
| Electrolyte imbalance | 43.35 | 18.77 | 25 | 5422 | 18008 | 56268612 |
| Product prescribing error | 42.47 | 18.77 | 27 | 5420 | 23159 | 56263461 |
| Osmotic demyelination syndrome | 36.32 | 18.77 | 9 | 5438 | 600 | 56286020 |
| Hypopituitarism | 36.21 | 18.77 | 10 | 5437 | 1018 | 56285602 |
| Oesophageal disorder | 32.72 | 18.77 | 11 | 5436 | 2169 | 56284451 |
| Premature baby | 31.81 | 18.77 | 21 | 5426 | 19184 | 56267436 |
| Blood sodium increased | 31.29 | 18.77 | 11 | 5436 | 2477 | 56284143 |
| Labelled drug-disease interaction medication error | 30.16 | 18.77 | 6 | 5441 | 144 | 56286476 |
| Insulin-like growth factor decreased | 29.57 | 18.77 | 7 | 5440 | 385 | 56286235 |
| Hypoosmolar state | 28.97 | 18.77 | 6 | 5441 | 177 | 56286443 |
| Brain oedema | 28.22 | 18.77 | 17 | 5430 | 13254 | 56273366 |
| Polyuria | 28.09 | 18.77 | 14 | 5433 | 7537 | 56279083 |
| Oligohydramnios | 28.02 | 18.77 | 13 | 5434 | 5981 | 56280639 |
| Exposure during pregnancy | 27.30 | 18.77 | 48 | 5399 | 136294 | 56150326 |
| Foetal exposure during pregnancy | 27.13 | 18.77 | 24 | 5423 | 33799 | 56252821 |
| Headache | 25.41 | 18.77 | 114 | 5333 | 558930 | 55727690 |
| Thoracotomy | 25.34 | 18.77 | 4 | 5443 | 23 | 56286597 |
| Abortion induced | 24.86 | 18.77 | 14 | 5433 | 9631 | 56276989 |
| Gastrointestinal infection | 24.62 | 18.77 | 13 | 5434 | 7881 | 56278739 |
| Neoplasm recurrence | 23.92 | 18.77 | 9 | 5438 | 2455 | 56284165 |
| Cutaneous lupus erythematosus | 23.51 | 18.77 | 9 | 5438 | 2575 | 56284045 |
| Hepatitis toxic | 22.35 | 18.77 | 9 | 5438 | 2943 | 56283677 |
| Germ cell cancer | 21.89 | 18.77 | 4 | 5443 | 60 | 56286560 |
| Blood sodium abnormal | 21.15 | 18.77 | 6 | 5441 | 674 | 56285946 |
| Hypothalamo-pituitary disorder | 20.98 | 18.77 | 6 | 5441 | 694 | 56285926 |
| Urine output decreased | 20.86 | 18.77 | 13 | 5434 | 10764 | 56275856 |
| Thirst | 20.51 | 18.77 | 13 | 5434 | 11077 | 56275543 |
| Urine sodium increased | 20.15 | 18.77 | 4 | 5443 | 95 | 56286525 |
| Insulin-like growth factor increased | 19.68 | 18.77 | 6 | 5441 | 865 | 56285755 |
| Nephrogenic diabetes insipidus | 19.49 | 18.77 | 6 | 5441 | 894 | 56285726 |
| Disseminated intravascular coagulation | 19.14 | 18.77 | 15 | 5432 | 17870 | 56268750 |
| Encephalopathy | 18.78 | 18.77 | 20 | 5427 | 35305 | 56251315 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyponatraemia | 396.79 | 17.68 | 209 | 5134 | 73590 | 31618411 |
| Craniopharyngioma | 142.96 | 17.68 | 27 | 5316 | 270 | 31691731 |
| Water intoxication | 87.32 | 17.68 | 19 | 5324 | 402 | 31691599 |
| Diabetes insipidus | 85.39 | 17.68 | 27 | 5316 | 2513 | 31689488 |
| Chorioretinopathy | 72.96 | 17.68 | 21 | 5322 | 1418 | 31690583 |
| Osmotic demyelination syndrome | 62.52 | 17.68 | 16 | 5327 | 692 | 31691309 |
| Hyponatraemic encephalopathy | 59.85 | 17.68 | 10 | 5333 | 45 | 31691956 |
| Hypernatraemia | 59.49 | 17.68 | 28 | 5315 | 7635 | 31684366 |
| Head titubation | 52.10 | 17.68 | 12 | 5331 | 331 | 31691670 |
| Labelled drug-disease interaction medication error | 51.82 | 17.68 | 10 | 5333 | 113 | 31691888 |
| Seizure | 39.92 | 17.68 | 65 | 5278 | 99703 | 31592298 |
| Inappropriate antidiuretic hormone secretion | 38.59 | 17.68 | 24 | 5319 | 11363 | 31680638 |
| Renal salt-wasting syndrome | 38.15 | 17.68 | 9 | 5334 | 276 | 31691725 |
| Cogwheel rigidity | 36.27 | 17.68 | 12 | 5331 | 1288 | 31690713 |
| Germ cell cancer | 35.96 | 17.68 | 7 | 5336 | 83 | 31691918 |
| Extrapyramidal disorder | 35.37 | 17.68 | 23 | 5320 | 11755 | 31680246 |
| Hypopituitarism | 34.83 | 17.68 | 13 | 5330 | 1988 | 31690013 |
| Neoplasm recurrence | 34.13 | 17.68 | 13 | 5330 | 2101 | 31689900 |
| Polyuria | 33.13 | 17.68 | 19 | 5324 | 7764 | 31684237 |
| Duplicate therapy error | 31.60 | 17.68 | 7 | 5336 | 161 | 31691840 |
| Sedation complication | 31.06 | 17.68 | 11 | 5332 | 1448 | 31690553 |
| Serotonin syndrome | 29.88 | 17.68 | 25 | 5318 | 18748 | 31673253 |
| Reaction to excipient | 29.28 | 17.68 | 8 | 5335 | 446 | 31691555 |
| Epiphysiolysis | 28.98 | 17.68 | 6 | 5337 | 99 | 31691902 |
| Recalled product administered | 28.58 | 17.68 | 8 | 5335 | 488 | 31691513 |
| Rebound effect | 28.56 | 17.68 | 12 | 5331 | 2501 | 31689500 |
| Insulin-like growth factor decreased | 28.27 | 17.68 | 7 | 5336 | 264 | 31691737 |
| Hyperadrenocorticism | 27.93 | 17.68 | 6 | 5337 | 119 | 31691882 |
| Enuresis | 26.75 | 17.68 | 11 | 5332 | 2173 | 31689828 |
| Apnoeic attack | 26.46 | 17.68 | 7 | 5336 | 345 | 31691656 |
| Pharyngeal haemorrhage | 25.56 | 17.68 | 8 | 5335 | 719 | 31691282 |
| Blood sodium increased | 24.51 | 17.68 | 11 | 5332 | 2688 | 31689313 |
| Flushing | 23.24 | 17.68 | 27 | 5316 | 30101 | 31661900 |
| Compulsive shopping | 20.99 | 17.68 | 6 | 5337 | 395 | 31691606 |
| Implant site pruritus | 20.99 | 17.68 | 3 | 5340 | 3 | 31691998 |
| CNS germinoma | 20.99 | 17.68 | 3 | 5340 | 3 | 31691998 |
| Toxic neuropathy | 19.55 | 17.68 | 6 | 5337 | 505 | 31691496 |
| Off label use | 19.48 | 17.68 | 112 | 5231 | 347162 | 31344839 |
| Therapeutic response decreased | 19.19 | 17.68 | 23 | 5320 | 26486 | 31665515 |
| Akathisia | 18.97 | 17.68 | 13 | 5330 | 7240 | 31684761 |
| Polydipsia | 18.79 | 17.68 | 10 | 5333 | 3530 | 31688471 |
| Anticholinergic syndrome | 18.68 | 17.68 | 7 | 5336 | 1081 | 31690920 |
| Product use in unapproved indication | 18.39 | 17.68 | 47 | 5296 | 99124 | 31592877 |
| Insulin-like growth factor increased | 18.10 | 17.68 | 7 | 5336 | 1178 | 31690823 |
| Hyperthermia malignant | 17.74 | 17.68 | 8 | 5335 | 1976 | 31690025 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Hyponatraemia | 864.04 | 15.09 | 417 | 8768 | 159670 | 70759589 |
| Hyponatraemic encephalopathy | 215.45 | 15.09 | 37 | 9148 | 275 | 70918984 |
| Craniopharyngioma | 187.52 | 15.09 | 34 | 9151 | 356 | 70918903 |
| Diabetes insipidus | 167.07 | 15.09 | 49 | 9136 | 4622 | 70914637 |
| Water intoxication | 141.39 | 15.09 | 30 | 9155 | 739 | 70918520 |
| Hypernatraemia | 129.14 | 15.09 | 52 | 9133 | 12709 | 70906550 |
| Seizure | 106.58 | 15.09 | 123 | 9062 | 177839 | 70741420 |
| Recalled product administered | 95.74 | 15.09 | 22 | 9163 | 788 | 70918471 |
| Osmotic demyelination syndrome | 95.29 | 15.09 | 24 | 9161 | 1273 | 70917986 |
| Renal salt-wasting syndrome | 95.24 | 15.09 | 21 | 9164 | 622 | 70918637 |
| Hyponatraemic seizure | 93.89 | 15.09 | 20 | 9165 | 502 | 70918757 |
| Pharyngeal haemorrhage | 81.08 | 15.09 | 21 | 9164 | 1246 | 70918013 |
| Labelled drug-disease interaction medication error | 68.28 | 15.09 | 14 | 9171 | 290 | 70918969 |
| Germ cell cancer | 64.07 | 15.09 | 12 | 9173 | 152 | 70919107 |
| Hypopituitarism | 58.91 | 15.09 | 20 | 9165 | 3030 | 70916229 |
| Polyuria | 57.27 | 15.09 | 30 | 9155 | 13376 | 70905883 |
| Blood sodium decreased | 56.05 | 15.09 | 40 | 9145 | 30958 | 70888301 |
| Poor quality product administered | 53.37 | 15.09 | 19 | 9166 | 3312 | 70915947 |
| Brain injury | 51.84 | 15.09 | 26 | 9159 | 10591 | 70908668 |
| Neoplasm recurrence | 50.25 | 15.09 | 19 | 9166 | 3922 | 70915337 |
| Adrenocortical insufficiency acute | 45.74 | 15.09 | 16 | 9169 | 2650 | 70916609 |
| Blood sodium increased | 44.53 | 15.09 | 18 | 9167 | 4434 | 70914825 |
| Product prescribing error | 37.89 | 15.09 | 35 | 9150 | 38917 | 70880342 |
| Inappropriate antidiuretic hormone secretion | 37.46 | 15.09 | 28 | 9157 | 23248 | 70896011 |
| Tonsillar disorder | 37.02 | 15.09 | 11 | 9174 | 1083 | 70918176 |
| Chorioretinopathy | 36.82 | 15.09 | 13 | 9172 | 2212 | 70917047 |
| Insulin-like growth factor decreased | 34.17 | 15.09 | 9 | 9176 | 570 | 70918689 |
| Oligohydramnios | 32.06 | 15.09 | 13 | 9172 | 3227 | 70916032 |
| Flushing | 32.05 | 15.09 | 46 | 9139 | 82126 | 70837133 |
| Urine osmolarity decreased | 30.91 | 15.09 | 6 | 9179 | 93 | 70919166 |
| Head titubation | 30.65 | 15.09 | 9 | 9176 | 851 | 70918408 |
| Epiphysiolysis | 30.44 | 15.09 | 6 | 9179 | 101 | 70919158 |
| Duplicate therapy error | 30.42 | 15.09 | 7 | 9178 | 252 | 70919007 |
| Electrolyte imbalance | 29.81 | 15.09 | 26 | 9159 | 26835 | 70892424 |
| Hyperadrenocorticism | 28.74 | 15.09 | 7 | 9178 | 323 | 70918936 |
| Oesophageal disorder | 27.99 | 15.09 | 11 | 9174 | 2519 | 70916740 |
| Polydipsia | 27.29 | 15.09 | 14 | 9171 | 5974 | 70913285 |
| Rheumatoid arthritis | 27.25 | 15.09 | 3 | 9182 | 291802 | 70627457 |
| Nephrogenic diabetes insipidus | 26.98 | 15.09 | 10 | 9175 | 1953 | 70917306 |
| Contraindicated product prescribed | 26.06 | 15.09 | 9 | 9176 | 1434 | 70917825 |
| Abortion induced | 25.96 | 15.09 | 14 | 9171 | 6611 | 70912648 |
| Epistaxis | 25.72 | 15.09 | 47 | 9138 | 102580 | 70816679 |
| Therapeutic response decreased | 24.68 | 15.09 | 34 | 9151 | 58419 | 70860840 |
| Hypoosmolar state | 24.63 | 15.09 | 6 | 9179 | 277 | 70918982 |
| Rebound effect | 24.47 | 15.09 | 13 | 9172 | 5958 | 70913301 |
| Apnoeic attack | 24.43 | 15.09 | 7 | 9178 | 607 | 70918652 |
| Hypothalamo-pituitary disorder | 24.41 | 15.09 | 8 | 9177 | 1087 | 70918172 |
| Insulin-like growth factor increased | 24.26 | 15.09 | 9 | 9176 | 1762 | 70917497 |
| Thoracotomy | 23.80 | 15.09 | 5 | 9180 | 117 | 70919142 |
| Reaction to excipient | 22.16 | 15.09 | 8 | 9177 | 1450 | 70917809 |
| Product use in unapproved indication | 22.10 | 15.09 | 68 | 9117 | 207410 | 70711849 |
| Headache | 21.85 | 15.09 | 139 | 9046 | 580266 | 70338993 |
| Urine sodium increased | 21.47 | 15.09 | 5 | 9180 | 190 | 70919069 |
| Cutaneous lupus erythematosus | 20.13 | 15.09 | 9 | 9176 | 2839 | 70916420 |
| Urine output decreased | 19.99 | 15.09 | 17 | 9168 | 16953 | 70902306 |
| Cogwheel rigidity | 19.77 | 15.09 | 9 | 9176 | 2959 | 70916300 |
| Urine osmolarity increased | 19.64 | 15.09 | 5 | 9180 | 277 | 70918982 |
| Off label use | 19.38 | 15.09 | 163 | 9022 | 742897 | 70176362 |
| Gastrointestinal infection | 18.90 | 15.09 | 13 | 9172 | 9478 | 70909781 |
| Joint swelling | 18.43 | 15.09 | 5 | 9180 | 253206 | 70666053 |
| Nasal discomfort | 18.41 | 15.09 | 10 | 9175 | 4791 | 70914468 |
| Pituitary tumour benign | 18.05 | 15.09 | 8 | 9177 | 2471 | 70916788 |
| Akathisia | 18.04 | 15.09 | 14 | 9171 | 12279 | 70906980 |
| Drug interaction | 17.98 | 15.09 | 97 | 9088 | 381344 | 70537915 |
| Thirst | 17.92 | 15.09 | 15 | 9170 | 14634 | 70904625 |
| Toxic neuropathy | 17.91 | 15.09 | 6 | 9179 | 872 | 70918387 |
| Drug hypersensitivity | 17.63 | 15.09 | 6 | 9179 | 262453 | 70656806 |
| Metastases to pituitary gland | 17.62 | 15.09 | 3 | 9182 | 21 | 70919238 |
| Hyperthermia malignant | 17.51 | 15.09 | 8 | 9177 | 2653 | 70916606 |
| Drug intolerance | 17.31 | 15.09 | 4 | 9181 | 225683 | 70693576 |
| Extrapyramidal disorder | 17.06 | 15.09 | 17 | 9168 | 20733 | 70898526 |
| Foetal growth restriction | 16.62 | 15.09 | 7 | 9178 | 1912 | 70917347 |
| Urine output increased | 16.58 | 15.09 | 7 | 9178 | 1924 | 70917335 |
| Hepatitis toxic | 16.04 | 15.09 | 9 | 9176 | 4590 | 70914669 |
| Exposure during pregnancy | 15.78 | 15.09 | 35 | 9150 | 87682 | 70831577 |
| Generalised tonic-clonic seizure | 15.76 | 15.09 | 23 | 9162 | 41638 | 70877621 |
| Dihydrotestosterone increased | 15.48 | 15.09 | 3 | 9182 | 46 | 70919213 |
| Arthralgia | 15.37 | 15.09 | 26 | 9159 | 503364 | 70415895 |
| Pain | 15.35 | 15.09 | 37 | 9148 | 628779 | 70290480 |
| Brain oedema | 15.35 | 15.09 | 17 | 9168 | 23401 | 70895858 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | H01BA02 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES POSTERIOR PITUITARY LOBE HORMONES Vasopressin and analogues |
| FDA CS | M0022562 | Vasopressins |
| CHEBI has role | CHEBI:33295 | diagnostic aid |
| CHEBI has role | CHEBI:35846 | renal agents |
| CHEBI has role | CHEBI:59727 | arginine vasopressin receptor agonist |
| MeSH PA | D050034 | Antidiuretic Agents |
| MeSH PA | D003029 | Coagulants |
| MeSH PA | D006401 | Hematologic Agents |
| MeSH PA | D006490 | Hemostatics |
| MeSH PA | D045283 | Natriuretic Agents |
| FDA EPC | N0000175905 | Vasopressin Analog |
| FDA PE | N0000175914 | Increased Coagulation Factor VIII Activity |
| FDA PE | N0000175915 | Increased Coagulation Factor VIII Concentration |
| FDA EPC | N0000175916 | Factor VIII Activator |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Nocturnal enuresis | indication | 8009008 | |
| Hereditary factor VIII deficiency disease | indication | 28293008 | DOID:12134 |
| Polyuria | indication | 28442001 | |
| von Willebrand disorder | indication | 128105004 | DOID:12531 |
| Partial Central Diabetes Insipidus | indication | ||
| Uremic Bleeding Tendency | off-label use | ||
| Psychogenic polydipsia | contraindication | 15945005 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Chronic heart failure | contraindication | 48447003 | |
| Upper respiratory infection | contraindication | 54150009 | |
| Allergic rhinitis | contraindication | 61582004 | |
| Nasal discharge | contraindication | 64531003 | |
| Nasal congestion | contraindication | 68235000 | |
| Water intoxication syndrome | contraindication | 71785001 | |
| Hyponatremia | contraindication | 89627008 | |
| Cystic fibrosis | contraindication | 190905008 | DOID:1485 |
| Impaired renal function disorder | contraindication | 197663003 | |
| Finding of excessive fluid intake | contraindication | 267026004 | |
| Hereditary von Willebrand disease type 2B | contraindication | 359717002 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Severe Allergic Rhinitis | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.65 | acidic |
| pKa2 | 12.27 | acidic |
| pKa3 | 12.64 | acidic |
| pKa4 | 12.94 | acidic |
| pKa5 | 13.39 | acidic |
| pKa6 | 13.43 | acidic |
| pKa7 | 13.8 | acidic |
| pKa8 | 10.75 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.0277MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 9220747 | May 7, 2023 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0277MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 9504647 | May 7, 2023 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0277MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 9919025 | May 7, 2023 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0553MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 9220747 | May 7, 2023 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0553MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 9504647 | May 7, 2023 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0553MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 9919025 | May 7, 2023 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0277MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 8802624 | Dec. 29, 2023 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0553MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 8802624 | Dec. 29, 2023 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0277MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 7560429 | Feb. 2, 2024 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0553MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 7560429 | Feb. 2, 2024 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0277MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 11020448 | May 21, 2029 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION |
| 0.0553MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 10137167 | May 21, 2029 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION |
| 0.0277MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 9974826 | April 13, 2030 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| 0.0553MG | NOCDURNA | FERRING PHARMS INC | N022517 | June 21, 2018 | RX | TABLET | SUBLINGUAL | 9974826 | April 13, 2030 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENTS SERUM SODIUM CONCENTRATION |
| 0.00083MG/SPRAY | NOCTIVA | SERENITY PHARMS LLC | N201656 | March 3, 2017 | DISCN | SPRAY, METERED | NASAL | 11419914 | June 15, 2030 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN |
| 0.00166MG/SPRAY | NOCTIVA | SERENITY PHARMS LLC | N201656 | March 3, 2017 | DISCN | SPRAY, METERED | NASAL | 11419914 | June 15, 2030 | TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN |
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Vasopressin V2 receptor | GPCR | AGONIST | Ki | 8.30 | CHEMBL | SCIENTIFIC LITERATURE | |||
| Vasopressin V1b receptor | GPCR | Ki | 9.43 | CHEMBL | |||||
| Oxytocin receptor | GPCR | AGONIST | Ki | 7.60 | IUPHAR | ||||
| Vasopressin V1a receptor | GPCR | Ki | 8.42 | CHEMBL | |||||
| Oxytocin receptor | GPCR | Ki | 9.01 | CHEMBL | |||||
| Vasopressin V1a receptor | GPCR | Ki | 7.97 | CHEMBL | |||||
| Vasopressin V1b receptor | GPCR | Ki | 9.70 | CHEMBL | |||||
| Vasopressin V2 receptor | GPCR | Ki | 9.10 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019709 | VUID |
| N0000170340 | NUI |
| D00291 | KEGG_DRUG |
| 62357-86-2 | SECONDARY_CAS_RN |
| 203658 | RXNORM |
| 4018750 | VANDF |
| 4019709 | VANDF |
| C0011701 | UMLSCUI |
| CHEBI:4450 | CHEBI |
| CHEMBL376685 | ChEMBL_ID |
| CHEMBL1429 | ChEMBL_ID |
| CHEMBL1200556 | ChEMBL_ID |
| DB00035 | DRUGBANK_ID |
| 2182 | IUPHAR_LIGAND_ID |
| 3799 | INN_ID |
| ENR1LLB0FP | UNII |
| 5311065 | PUBCHEM_CID |
| 1069 | MMSL |
| 4548 | MMSL |
| 48087 | MMSL |
| 772 | MMSL |
| d00583 | MMSL |
| 002125 | NDDF |
| 004784 | NDDF |
| 126189002 | SNOMEDCT_US |
| 126190006 | SNOMEDCT_US |
| 73454001 | SNOMEDCT_US |
| D003894 | MESH_DESCRIPTOR_UI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Stimate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0053-6871 | SPRAY, METERED | 1.50 mg | NASAL | NDA | 23 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0517-4310 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 20 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2464 | TABLET | 0.10 mg | ORAL | ANDA | 19 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2464 | TABLET | 0.10 mg | ORAL | ANDA | 19 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2465 | TABLET | 0.20 mg | ORAL | ANDA | 19 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2465 | TABLET | 0.20 mg | ORAL | ANDA | 19 sections |
| Desmopressin acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-5051 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 21 sections |
| Desmopressin acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0703-5054 | INJECTION | 4 ug | INTRAVENOUS | ANDA | 21 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-169 | TABLET | 0.10 mg | ORAL | ANDA | 11 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10702-170 | TABLET | 0.20 mg | ORAL | ANDA | 11 sections |
| Desmopressin Acetate | Human Prescription Drug Label | 1 | 16714-015 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 19 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-883 | TABLET | 0.10 mg | ORAL | ANDA | 19 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-884 | TABLET | 0.20 mg | ORAL | ANDA | 19 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-489 | TABLET | 0.10 mg | ORAL | ANDA | 20 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-489 | TABLET | 0.10 mg | ORAL | ANDA | 20 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-490 | TABLET | 0.20 mg | ORAL | ANDA | 20 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 23155-490 | TABLET | 0.20 mg | ORAL | ANDA | 20 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24208-342 | SOLUTION | 0.10 mg | NASAL | ANDA | 27 sections |
| desmopressin acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-460 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 21 sections |
| desmopressin acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-461 | INJECTION, SOLUTION | 40 ug | INTRAVENOUS | ANDA | 20 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-053 | INJECTION, SOLUTION | 4 ug | INTRAVENOUS | ANDA | 25 sections |
| DESMOPRESSIN ACETATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-931 | INJECTION | 4 ug | SUBCUTANEOUS | ANDA | 13 sections |
| Desmopressin Acetate | Human Prescription Drug Label | 1 | 47335-788 | SOLUTION | 0.10 mg | NASAL | ANDA | 24 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-220 | TABLET | 0.10 mg | ORAL | ANDA | 19 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-221 | TABLET | 0.20 mg | ORAL | ANDA | 19 sections |
| NOCDURNA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54436-325 | TABLET | 27.70 ug | SUBLINGUAL | NDA | 29 sections |
| NOCDURNA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54436-350 | TABLET | 55.30 ug | SUBLINGUAL | NDA | 29 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-1129 | TABLET | 0.20 mg | ORAL | ANDA | 11 sections |
| Desmopressin Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-5602 | SOLUTION | 0.10 mg | NASAL | ANDA | 21 sections |
| DDAVP | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55566-2200 | INJECTION | 4 ug | INTRAVENOUS | NDA | 31 sections |